MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701

The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)

(2016) Andrew M. Kidger et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Epidermal growth factor–stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis

(2015) Camilo Garay et al.   MOLECULAR BIOLOGY OF THE CELL

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

(2015) C. Bartholomeusz et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2

(2015) Sergey V. Karakashev et al.   Oncotarget

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

(2015) Ryan B. Corcoran et al.   Oncotarget

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer

(2014) James M. Lindberg et al.   NEOPLASIA

Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation

(2013) Kanae Sato et al.   CANCER SCIENCE

Mutations of theBRAFgene in human cancer, by Davieset al. (Nature2002; 417: 949-54)

(2013) G. W. M. Millington   CLINICAL AND EXPERIMENTAL DERMATOLOGY

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis

(2012) Meiling Gao et al.   EMBO Molecular Medicine

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments

(2012) Katia Cortese et al.   MOLECULAR BIOLOGY OF THE CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Feedback regulation of EGFR signalling: decision making by early and delayed loops

(2011) Roi Avraham et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

(2009) O. K. Mirzoeva et al.   CANCER RESEARCH

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

BRAF Signaling and Targeted Therapies in Melanoma

(2009) Nathalie Dhomen et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

(2009) Y.-K. Yoon et al.   MOLECULAR CANCER THERAPEUTICS

Ras/MAPK signaling from endomembranes

(2009) Nicole Fehrenbacher et al.   Molecular Oncology

ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling

(2008) Xin Li et al.   CELLULAR SIGNALLING

Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for Degradation

(2008) Sara Sigismund et al.   DEVELOPMENTAL CELL

Endocytosis and intracellular trafficking of ErbBs

(2008) Alexander Sorkin et al.   EXPERIMENTAL CELL RESEARCH

Geldanamycin-Induced Down-Regulation of ErbB2 from the Plasma Membrane Is Clathrin Dependent but Proteasomal Activity Independent

(2008) N. M. Pedersen et al.   MOLECULAR CANCER RESEARCH

Effectively targeting BRAF in melanoma: a formidable challenge

(2008) Leslie A Fecher et al.   Pigment Cell & Melanoma Research